度洛西汀治疗躯体化障碍的疗效评价

目的探讨度洛西汀治疗躯体化障碍的疗效。方法将82例躯体化障碍的患者进行为期6周治疗。采用SCL-90评定疗效，副反应量表（TESS）评定副反应，疗效评定以减分率及有效率为评定指标。结果口服度洛西汀6周后有效率为84．15％，较2周、4周末显著提高（P〈0．01）；治疗前躯体化障碍患者SCL-90总分及各项因子分明显高于国内常模，躯体化、焦虑、抑郁、偏执因子分升高明显，治疗后各因子分较治疗前显著降低（P〈0．05），度洛西汀治疗副反应轻微。结论度洛西汀对躯体化障碍有较好疗效，而副反应较低。

Evaluations of curative effects of duloxetine in the treatment of patients with somatization disorder

Objective To study the effect of duloxetine in treatment of patients with somatization disorder. Methods Eighty-two patients with somatization disorder were treated with duloxetine 20 - 40 mg/d for weeks. The clinical effect and side effects was assessed by SCL-90 and TESS respectively. Results At the end of 6 weeks of treatment, the responsive rate was 84. 7%. All item scores of SCL-90 decreased（P 〈0.05） and its side effects were less. Conclusion Duloxetine is effective in the treatment of patients with somatization disorder and its side effects were less.